Compositions and methods for inhibiting norovirus infection
A composition for use in inhibiting the binding of a Norovirus to the histo-blood group antigen on the surface of epithelia is disclosed. The composition may contain a therapeutically effective amount of a binding-inhibiting compound and a carrier and/or excipient. The compounds may competitively bind a Norovirus that has the capability of binding with the histo-blood group antigens of secretor blood type, including A, B, AB, and O blood types. The compositions may be administered to a human prior to or after infection by a Norovirus, to prevent, ameliorate, or reduce the effects of an infection.
1. A method for the inhibition of norovirus in a subject in need thereof, comprising the step of administering to the subject a therapeutically effective amount of a compound that inhibits binding of at least one Norovirus to a native histo blood group antigen of the subject, wherein said compound comprises a steroid structure and is selected from the group consisting of
or a pharmaceutically acceptable salt thereof,
or a pharmaceutically acceptable salt thereof,
or a pharmaceutically acceptable salt thereof,
or a pharmaceutically acceptable salt thereof, and
or a pharmaceutically acceptable salt thereof,
and at least one diluent, carrier and or excipient.
2. A method for the inhibition of norovirus in a subject in need thereof comprising the step of administering to the subject a therapeutically effective amount of a compound that inhibits binding of at least one Norovirus to a native histo blood group antigen of the subject, wherein said compound is selected from any one of compound 1 through 21, pharmaceutically acceptable salts of compounds 1 through 21, or a combination thereof.
3. The method of claim 1 wherein said compound comprises
or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 wherein said compound comprises
or a pharmaceutically acceptable salt thereof.
5. The method of claim 1 wherein said compound comprises
or a pharmaceutically acceptable salt thereof.
6. The method of claim 1 wherein said compound comprises
or a pharmaceutically acceptable salt thereof.
7. The method of claim 1 wherein said compound comprises
or a pharmaceutically acceptable salt thereof.